Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity

BACKGROUND AND PURPOSE: Esophageal cancer incidence is increasing and is rarely curable. Hypoxic tumor areas cause resistance to conventional therapies, making them susceptible for treatment with hypoxia-activated prodrugs (HAPs). We investigated in vivo whether the HAP evofosfamide (TH-302) could i...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Radiother Oncol
Main Authors: Spiegelberg, Linda, van Hoof, Stefan J., Biemans, Rianne, Lieuwes, Natasja G., Marcus, Damiënne, Niemans, Raymon, Theys, Jan, Yaromina, Ala, Lambin, Philippe, Verhaegen, Frank, Dubois, Ludwig J.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier Scientific Publishers 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6913516/
https://ncbi.nlm.nih.gov/pubmed/31431383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2019.06.034
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki